Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187043
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lavilla Olleros, Cristina | - |
dc.contributor.author | Ausín García, Cristina | - |
dc.contributor.author | Bendala Estrada, Alejandro David | - |
dc.contributor.author | Muñoz, Ana | - |
dc.contributor.author | Wikman Jogersen, Philip Erick | - |
dc.contributor.author | Fernández Cruz, Ana | - |
dc.contributor.author | Giner Galvañ, Vicente | - |
dc.contributor.author | Vargas, Juan Antonio | - |
dc.contributor.author | Seguí Ripoll, José Miguel | - |
dc.contributor.author | Rubio Rivas, Manuel | - |
dc.contributor.author | Miranda Godoy, Rodrigo | - |
dc.contributor.author | Mérida Rodrigo, Luis | - |
dc.contributor.author | Fonseca Aizpuru, Eva | - |
dc.contributor.author | Arnalich Fernández, Francisco | - |
dc.contributor.author | Artero, Arturo | - |
dc.contributor.author | Loureiro Amigo, Jose | - |
dc.contributor.author | García García, Gema María | - |
dc.contributor.author | Corral Gudino, Luis | - |
dc.contributor.author | Jiménez Torres, Jose | - |
dc.contributor.author | Casas Rojo, José Manuel | - |
dc.contributor.author | Millán Núñez-Cortés, Jesús | - |
dc.contributor.author | On Behalf of the SEMI-COVID-19 Network | - |
dc.date.accessioned | 2022-06-27T08:55:45Z | - |
dc.date.available | 2022-06-27T08:55:45Z | - |
dc.date.issued | 2022-01-21 | - |
dc.identifier.uri | http://hdl.handle.net/2445/187043 | - |
dc.description.abstract | Objective To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Methods Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Results Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p < .001). Radiological and analytical findings showed a higher use of megadoses therapy among patients with an interstitial infiltrate and elevated inflammatory markers associated with COVID-19. In the univariate study it appears that steroid use is associated with increased mortality (OR 2.07 95% CI 1.91-2.24 p < .001) and megadose use with increased survival (OR 0.84 95% CI 0.75-0.96, p 0.011), but when adjusting for possible confounding factors, it is observed that the use of megadoses is also associated with higher mortality (OR 1.54, 95% CI 1.32-1.80; p < .001). There is no difference between megadoses and low-dose (p.298). Although, there are differences in the use of megadoses versus low-dose in terms of complications, mainly infectious, with fewer pneumonias and sepsis in the megadoses group (OR 0.82 95% CI 0.71-0.95; p < .001 and OR 0.80 95% CI 0.65-0.97; p < .001) respectively. Conclusion There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses. | - |
dc.format.extent | 17 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0261711 | - |
dc.relation.ispartof | PLOS ONE, 2022, vol. 17, num. 1, p. e0261711 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0261711 | - |
dc.rights | cc by (c) Lavilla Olleros, Cristina et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | Epidemiologia | - |
dc.subject.classification | Corticosteroides | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Epidemiology | - |
dc.subject.other | Adrenocortical hormones | - |
dc.title | Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-06-23T08:14:49Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35061713 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
journal.pone.0261711.pdf | 478.59 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License